[Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].
89 patients with a superficial tumor of the bladder were treated with intravesical BCG: 150 mg of the Pasteur strain was instilled once a week for 6 weeks, once every other week for 3 months and once a month for 2 years, in 4 groups of patients. Group I: 20 patients with primary carcinoma in situ (CIS); 18 have been monitored for more than 6 months: in each, cytology has become negative; 16 were controlled by TUR: in all but one complete regression of CIS was observed. Group II: 24 patients with stage O tumor; in 16, follow up is greater than 12 months : the recurrence rate dropped from 11.12/100 months patients to 1.52/100 months patients. Group III: 12 patients with stage A tumor: in 10, follow up is greater than 12 months; 2 patients had tumor recurrence. Group IV: 28 patients with stage O or stage A tumor associated with CIS; in 17, followup is greater than 12 months: CIS disappeared in 13, but in 2 recurrences were observed (stage O without CIS). In addition to irritative side effects on the bladder, we observed complications in four cases: epididymitis in 2 patients and BCG spread with granulomatous hepatitis and bronchopulmonary lesions in two others.
Steg
A
A
Leleu
C
C
Boccon-Gibod
L
L
Debré
B
B
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine
Traitement des tumeurs superficielles et des carcinomes in situ de vessie par BCG-thérapie intravésicale.